Introduction
The tumor suppressors p19 ARF and p53 are essential in blocking lymphoma development initiated by oncogenes. ARF and p53 mediate Myc-induced apoptosis in B cells, and consequently loss of ARF or p53 accelerates Mycinduced B-cell lymphomagenesis (Eischen et al., 1999; Schmitt et al., 1999) . Furthermore, in the lymphomas that arise in Em-myc transgenic mice, which overexpress Myc in the B-cell compartment (Adams et al., 1985) , ARF or p53 is inactivated in over half of these tumors (Eischen et al., 1999) . In addition, in lymphomas that emerge in ARF þ /À or p53
Em-myc transgenics, the second allele of ARF or p53 is deleted in 77 or 100% of these tumors, respectively (Eischen et al., 1999; Schmitt et al., 1999) . Therefore, ARF and p53 guard against oncogene-initiated tumorigenesis by activating apoptosis and consequently, are frequently targeted for inactivation in lymphomas that overexpress oncogenes.
Mdm2 is a key intermediary in the ARF-p53 tumor suppressor pathway. Mdm2 functions as an E3 ubiquitin ligase, and inactivates p53 by ubiquitylating and targeting it for degradation by the proteasome (Honda et al., 1997; Freedman and Levine, 1998; Roth et al., 1998) . Mdm2 can also bind to p53 and block its transactivation functions (Momand et al., 1992) . ARF is a nucleolar protein and regulates p53 by binding to Mdm2 and blocking Mdm2's ability to ubiquitylate p53 and to inhibit p53 transcription functions Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998; Honda and Yasuda, 1999) . Whereas ARF or p53 is commonly inactivated in cancers, Mdm2 is frequently overexpressed in murine and human malignancies, including lymphomas (Watanabe et al., 1996; Momand et al., 1998; Eischen et al., 1999) . Thus, ARF, Mdm2, and p53 function together to suppress tumor development.
In vitro and in vivo experiments have shown that Mdm2 is necessary to regulate p53 activity during development and under stressful conditions, such as oncogene overexpression and following DNA damage. Firstly, early embryonic lethality of Mdm2-null embryos is rescued by loss of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995) . Secondly, deleting p53 blocks Mdm2 haploinsufficient B cells from undergoing spontaneous and Myc-induced apoptosis (Alt et al., 2003) . Thirdly, mice engineered to express low levels of Mdm2 (hypomorphic) are more sensitive to apoptosis and death induced by gamma radiation, which is rescued by loss of p53 (Mendrysa et al., 2003) . Finally, lymphomas that arise in Mdm2 þ /À Em-myc transgenic mice preferentially harbor mutations that inactivate p53 (Alt et al., 2003) . Therefore, a certain threshold of Mdm2 is required to harness p53 activity under stressful conditions, and failure to do so results in apoptosis.
Although at face value the p53 tumor suppressor pathway appears linear, complicated feedback control mechanisms are also operational in the pathway (Wu et al., 1993; Stott et al., 1998) . For example, Mdm2 is a direct transcription target upregulated by p53 Juven et al., 1993; Perry et al., 1993; Wu et al., 1993) , whereas ARF expression is elevated in cells lacking p53 or in cells harboring p53 mutations, and this appears to be Mdm2-independent Zindy et al., 1998) . However, Mdm2 expression can also influence ARF function in certain situations. For example, ARF overexpression fails to induce a cell cycle arrest in p53-null cells (Kamijo et al., 1997) , yet is capable of doing so in cells lacking both p53 and Mdm2 . Furthermore, in fibroblasts and B cells, the induction of p53 by oncogenes requires ARF (Robertson and Jones, 1998; Stott et al., 1998; Zindy et al., 1998; Eischen et al., 1999) , yet nucleolar sequestration of Mdm2 by ARF is not necessarily required for p53 activation (Korgaonkar et al., 2002) . Collectively, these findings underscore the complexity of the ARF/Mdm2/p53 network and, in particular, the consequences of ARF : Mdm2 interactions on cell survival and transformation are not resolved. Here we report that loss of only one allele of ARF fully compensates for the effects of Mdm2 haploinsufficiency in B-cell development, survival, and transformation in Em-myc transgenic mice. The results support the model whereby the stoichiometry of the ARF-Mdm2 complex is a critical arbiter of cell survival and transformation.
Results

ARF loss rescues the spontaneous apoptosis of Mdm2
þ /À
pre-B cells
Bone marrow-derived primary Mdm2 þ /À pre-B cells undergo spontaneous apoptosis in tissue culture and therefore do not grow (Alt et al., 2003) , whereas pre-B cells lacking ARF are resistant to spontaneous apoptosis and can proliferate indefinitely (Eischen et al., 1999; Randle et al., 2001) . p53 mediates the spontaneous apoptosis of Mdm2 þ /À pre-B cells (Alt et al., 2003) , yet the influence ARF had on this process was unclear. We therefore evaluated whether loss of ARF would influence the survival and growth of Mdm2 þ /À pre-B cells in vitro.
, and wild-type littermate mice was placed into IL-7-containing medium, which selects for pre-B cells that emerge within 14 days (Eischen et al., 1999) . As previously reported, ARF-null pre-B cells grew more rapidly than wild-type pre-B cells (Figure 1 ; Eischen et al., 1999) . In contrast to Mdm2 þ /À pre-B cells, ARF À/À Mdm2 þ /À pre-B cells emerged from bone marrow and proliferated as well as wild-type pre-B cells (Figure 1 ). To determine whether the differences in the rates of proliferation were attributable to differences in apoptosis, we measured cell viability and DNA fragmentation in the bone marrow cultures. As anticipated, the high rates of spontaneous apoptosis of Mdm2 þ /À bone marrow cells (o29% viable at day 18; Alt et al., 2003) were fully rescued by loss of ARF, as ARF À/À
Mdm2
þ /À bone marrow cultures consistently had low apoptotic indices (>86% viable at day 18) similar to those of wild-type cultures (>89% viable at day 18). Therefore, ARF loss fully compensates for the apoptosis sensitivity conferred by Mdm2 haploinsufficiency in pre-B cells. Furthermore, as the rates of growth of wild-type and ARF
pre-B cells were similar, these results also suggest that Mdm2 haploinsufficiency restores normal proliferative rates even in cells lacking ARF.
Loss of one allele of ARF inhibits the increased p53 activity in Mdm2 þ /À lymphocytes Previously, we established that p53 mediated the spontaneous apoptosis of Mdm2 haploinsufficient B cells (Alt et al., 2003) . In addition, thymocytes from mice with an Mdm2 hypomorphic allele showed an increase in p53 transcriptional activity (Mendrysa et al., 2003) . To determine whether a deficiency in ARF rescues apoptosis of Mdm2 þ /À B cells by inhibiting p53, we evaluated p53 induction and activity following gamma irradiation of mice with both alleles or only one allele of mice (circles), two wild-type mice (squares), and two Mdm2 þ /À mice (crosses) was placed into IL-7-containing medium on day 0. Cells were counted at the indicated intervals, and net population doublings of the pre-B cells was calculated. Trypan blue dye exclusion was used to determine viability and propidium iodide (PI) staining followed by flow cytometry verified cell death was apoptosis Mdm2 and/or ARF. As expected, the levels of p53 and the p53 transcriptional target p21 in unirradiated splenocytes from wild-type and Mdm2 þ /À mice were below the level of detection (Figure 2a ). Additionally, steady-state levels of Mdm2 were reduced in Mdm2 þ /À splenocytes when compared to splenocytes from wildtype mice (Figure 2a) . Following gamma irradiation, p53 protein is stabilized and activated resulting in increased levels of the p53 transcriptional targets Mdm2 and p21 in all genotypes analyzed (Figures 2a  and b) . Specifically, Mdm2 protein was upregulated by gamma irradiation in splenocytes from Mdm2 þ /À and ARF
þ /À mice, but not to the same extent as in irradiated wild-type and ARF þ /À splenocytes (Figures 2a  and b) . In contrast, the levels of p21 were higher in splenocytes from irradiated Mdm2 þ /À mice when compared to p21 levels in splenocytes from irradiated wildtype and ARF þ /À mice (Figures 2a and b) . Importantly, the increased levels of p21 in irradiated Mdm2 þ /À splenocytes were consistently reduced in mice haploinsufficient for both Mdm2 and ARF (Figure 2b ). The increased p53 activity in Mdm2 þ /À splenocytes was not accompanied by an increase in p53 protein levels, as all genotypes had similar levels of p53 following irradiation (Figures 2a and b) . This result is consistent with experiments on thymocytes that have an Mdm2 hypomorphic allele (Mendrysa et al., 2003) . Therefore, loss of one allele of ARF inhibits p53 transcriptional activity in Mdm2 þ /À lymphocytes without altering the levels of p53.
ARF haploinsufficiency impairs accelerated rates of Mycinduced apoptosis in Mdm2 þ /À B cells
Resistance to p53-and ARF-mediated apoptosis is a rate-limiting step in Myc-induced lymphomagenesis (Eischen et al., 1999; Schmitt et al., 1999) , and loss of one allele of ARF reduces p53 activity in Mdm2
lymphocytes. To address the effects of ARF loss on Myc-induced apoptosis in the context of Mdm2 heterozygosity, we isolated bone marrow from Em-myc transgenic mice heterozygous for Mdm2 and/or ARF prior to lymphoma onset. Bone marrow from ARF þ /À Em-myc transgenics explanted into tissue culture (day 0) grew as well as bone marrow from wild-type Em-myc transgenic mice ( Figure 3 ). As previously reported, Mdm2
Em-myc transgenic bone marrow was unable to grow ex vivo (Figure 3 ), due to very high rates of spontaneous apoptosis (Alt et al., 2003) . In contrast, ARF
Em-myc transgenic bone marrow did survive explantation and proliferate, with pre-B cells emerging in 9 days ( Figure 3 ). However, the ARF
Em-myc pre-B cells never grew as well as wildtype or ARF þ /À Em-myc transgenic pre-B cells, due to the higher rates of spontaneous apoptosis in these cultures, which were consistently o75% viable. Due to the rapid development of lymphoma in
Em-myc transgenics (see below), transformed precursor B cells were always present in the bone marrow cultures, which excluded the mice from these and other analyses. It should also be noted that although the wild-type, Figure 2 The increased p53 transcriptional activity in Mdm2
lymphocytes is inhibited by loss of a single allele of ARF. Figure 3 The sensitivity of Mdm2 heterozygous bone marrow to Myc-induced apoptosis ex vivo is partially rescued by loss of one allele of ARF. Prior to any detectable lymphoma, bone marrow from one ARF þ /À Em-myc transgenic mouse (crosses), two wild-type Em-myc transgenics (squares), two ARF þ /À Mdm2 þ /À Em-myc transgenics (circles), and two Mdm2 þ /À Em-myc transgenic mice (triangles) was placed into IL-7-containing medium on day 0. At the indicated intervals, cells were counted, and pre-B-cell growth was calculated as net population doublings. Trypan blue dye exclusion was used to determine viability and apoptosis was measured by PI staining followed by flow cytometry
þ /À Em-myc transgenic bone marrow explants proliferated in the first 15 days, all of the cells died by day 25 irrespective of genotype due to Myc transgene expression, as previously reported for wild-type Em-myc transgenic bone marrow cells (Eischen et al., 1999) . Therefore, Mdm2 haploinsufficient B cells are particularly prone to undergo apoptosis ex vivo especially when Myc is overexpressed, and loss of a single allele of ARF only partially rescues the combined effects of Myc overexpression and stress from tissue culture conditions.
To determine whether a deficiency in ARF rescues Mdm2 þ /À B cells from the apoptotic effects of Myc overexpression without the added stresses of tissue culture, apoptosis in vivo was measured. Specifically, splenocytes from Em-myc transgenics doubly heterozygous for Mdm2 and ARF and from control mice were analyzed for apoptosis prior to any detectable disease. The apoptotic index of splenocytes from nontransgenic Mdm2 þ /À mice was slightly higher than that of wild-type, ARF (Adams et al., 1985; Langdon et al., 1986) . Notably, spleens in ARF
Em-myc transgenics had normal numbers of mature (41%) B cells and also lacked precursor B cells (Figure 5 ), indicating a complete rescue of the B-cell developmental defects observed in Mdm2 þ /À Em-myc transgenic mice. In addition, there were similar numbers of peripheral blood lymphocytes in ARF
Em-myc transgenics as compared to wild-type Em-myc transgenic mice (data not shown). Therefore, an ARF deficiency rescues the negative effects of Myc overexpression and Mdm2 haploinsufficiency on B-cell development and survival in vivo.
ARF haploinsufficiency reverses the deleterious effects of Mdm2 haploinsufficiency on Myc-induced lymphomagenesis
Em-myc transgenic mice lacking ARF and/or p53 develop lymphomas at highly accelerated rates (Eischen et al., 1999; Schmitt et al., 1999) , whereas Mdm2 þ /À Emmyc transgenics have a protracted rate of lymphoma development (Alt et al., 2003) . Given the effects of loss of a single ARF allele in rescuing B-cell development and survival in Mdm2
Em-myc transgenics, we tested whether ARF haploinsufficiency would also restore the normal course of lymphoma development in Mdm2 B cells to Myc-induced apoptosis in vivo. PI-stained splenocytes from Em-myc transgenic negative (TgÀ) and Em-myc transgenic positive (Tg þ ) of the indicated genotypes prior to any detectable disease were analyzed by flow cytometry. DNA with less than 2N content (sub-G1) was quantitated from two (wild-type TgÀ, Em-myc transgenics were typical pre-B/B-cell lymphomas and developed in the peripheral lymph nodes and spleen, as is characteristic of lymphomas arising in wild type and ARF þ /À Emmyc transgenics (Adams et al., 1985; Eischen et al., 1999) . Therefore, since ARF heterozygosity rescues the effects of Mdm2 haploinsufficiency, and a decrease in Mdm2 compensates for a deficiency in ARF, these results suggest that the stoichiometry of both ARF and Mdm2 is a critical determinant of the rate of lymphomagenesis.
Inactivation of both p53 and ARF is selected for in lymphomas arising in ARF
Em-myc transgenics
Previously we reported that Mdm2 haploinsufficiency mediates its inhibitory effects on Myc-induced lymphomagenesis through activation of p53 (Alt et al., 2003) . Moreover, loss of functional p53 is the dominant alteration observed in lymphomas that arise in Em-myc transgenics (Eischen et al., 1999; Schmitt et al., 1999) , and this selection becomes over-riding in the context of an Mdm2 haploinsufficiency (Alt et al., 2003) . By contrast, in ARF þ /À Em-myc transgenics, nearly all of the lymphomas suffered loss of the second allele of ARF, and none of these tumors had mutations or deletions in p53 (Eischen et al., 1999) . We therefore addressed the status of ARF and p53 in the B-cell lymphomas that arose in ARF
Em-myc transgenics. Notably, p53 mutations were detected in 22% of the lymphomas Table 1 ), a frequency analogous to that observed in lymphomas from wildtype Em-myc transgenics (24%) (Eischen et al., 1999) . Mutant p53 protein was overexpressed in these lymphomas and all bore missense mutations in the p53 DNA-binding domain, the hot spot region for mutations. For example, p53 mutations at codons 270 and 242 were identified in lymphomas from ARF
Em-myc transgenic mice, and these two codons are those most frequently mutated in p53 in human cancer (codons 273 and 245, respectively) (Hainaut et al., 1998) . Similar to wild-type Em-myc transgenics (Eischen et al., 1999) , we failed to detect alterations in ARF, Mdm2, or p53 in 13% of the lymphomas emerging in ARF
Em-myc transgenics (Figures 7a and b , Table 1 ). ARF protein is normally not detectable in unstressed tissues and cells (Kamijo et al., 1997; Zindy et al., 1998) ; therefore, all lymphomas that did not overexpress ARF were evaluated for ARF deletions. Importantly, in lymphomas arising in ARF
Em-myc transgenics, 43.5% had deleted the remaining wild-type ARF allele (Figure 7b, Table 1 ), an exceedingly rare event in Mdm2 þ /À Em-myc transgenic lymphomas (4%) (Alt et al., 2003) . Not a single p53 deletion was detected in any of the lymphomas from ARF
Em-myc transgenic mice (Table 1) . Thus, loss of one allele of Mdm2 drives the selection of p53 mutations in ARF þ /À Em-myc transgenic lymphomas, and is associated with a corresponding decrease in lymphomas displaying loss of heterozygosity of ARF.
p53 can also be inactivated by Mdm2 overexpression (reviewed in Momand et al., 2000) . Mdm2 protein is overexpressed in approximately half of the lymphomas that arise in wild-type Em-myc transgenics (Eischen et al., 1999) and is also overexpressed in lymphomas having inactivated ARF or p53 (Eischen et al., 1999 (Eischen et al., , 2001 Alt et al., 2003) . Analysis of all the lymphomas from ARF
Em-myc transgenics revealed that 57% (13 of 23) of these lymphomas overexpressed Mdm2 (Figure 7a , Table 1 ), strengthening the notion that Mdm2 over- Figure 7a) expression is selected for during Myc-induced lymphomagenesis. Of the lymphomas that had deleted ARF or mutated p53, Mdm2 was also overexpressed in over half of these lymphomas ( Figure 7 , Table 1 ). Thus, despite the fact that ARF
Em-myc transgenic mice are haploinsufficient for Mdm2, Mdm2 overexpression was selected for as frequently in ARF
þ /À Emmyc transgenics as in wild-type Em-myc transgenics during Myc-induced lymphomagenesis. Therefore, the levels of both ARF and Mdm2 together regulate p53 and dictate the spectrum of genetic alterations selected for during Myc-induced lymphomagenesis.
Discussion ARF, Mdm2, and p53 function in a pathway that inhibits lymphoma development by prompting apoptosis when oncogenes are overexpressed Eischen et al., 1999; Schmitt et al., 1999) . B cells lacking ARF and/or p53 are resistant to Myc-induced apoptosis (Eischen et al., 1999; Schmitt et al., 1999) , and accordingly B-cell lymphoma development is accelerated in Em-myc transgenics that lack ARF and/or p53 (Eischen et al., 1999; Schmitt et al., 1999) . However, when p53's negative regulator Mdm2 is limiting, as in Mdm2 þ /À mice, B cells are rendered exquisitely sensitive to p53-dependent apoptosis induced by Myc. As a net result, B-cell lymphoma development is markedly impaired in Mdm2 þ /À Em-myc transgenic mice, and the lymphomas that do arise in these mice have an increased frequency of p53 mutations (Alt et al., 2003) . Moreover, the rates of B-cell apoptosis and lymphomagenesis are analogous in p53 þ /À Em-myc transgenic and Mdm2
Em-myc transgenic mice (Alt et al., 2003) , indicating that p53 mediates the haploinsufficiency effects of Mdm2 in Em-myc transgenics. The results presented here reveal that regulation of p53-dependent apoptosis by Mdm2 is more complex than previously realized and underscore the importance of ARF as a stoichiometric regulator of Mdm2. Strikingly, our unpredicted results demonstrate that a loss of a single allele of ARF completely rescues the effects of Mdm2 haploinsufficiency on B-cell development, survival, and transformation in Em-myc transgenic mice. Rates of B-cell apoptosis and development of Bcell lymphoma in ARF
Em-myc transgenics were equivalent to those of wild-type Em-myc transgenics. Moreover, the increased transcriptional activity of p53 in Mdm2 þ /À lymphocytes was restored to wildtype levels with loss of one allele of ARF. Therefore, the threshold level of Mdm2 necessary to regulate p53 in Em-myc transgenics is re-established when a single allele of ARF is lost (Figure 8) . Similarly, it would follow that the levels of ARF required to harness Mdm2 activity in Em-myc transgenic mice are restored when there is a haploinsufficiency in Mdm2 (Figure 8 ). Taken together, these findings are consistent with the concept that there is a delicate balance of ARF and Mdm2, and pushing this equilibrium in either direction drastically alters p53 regulation, apoptosis, cancer development, and survival (Figure 8 ).
ARF regulates Mdm2 under stressful conditions
p53 expression must be strictly regulated in cells to inhibit its negative consequences on cell growth and survival. For example, a deficiency or inactivation of p53 results in the development of cancer, whereas uncontrolled p53 results in apoptosis and can lead to the death of the organism. As a guardian of p53, Mdm2 is itself also tightly regulated, and ARF is a key regulator in this respect (reviewed in Sherr and Weber, 2000) . Recent studies have suggested that control of p53 by ARF through Mdm2 occurs under specific stressful conditions and possibly in certain cell types. Specifically, ARF is required to regulate Mdm2 in cells placed into tissue culture and in lymphocytes and mouse embryo fibroblasts (MEFs) that overexpress Myc Eischen et al., 1999; Schmitt et al., 1999; Sherr and DePinho, 2000) . In contrast, other stimuli, including lethal doses of gamma irradiation, overexpression of the E2f1 oncogene, and the development of hematopoietic and nonhematopoietic cells, do not appear to rely on Mdm2 regulation by ARF (Kamijo et al., 1997, 1999 ; Figure 8 Stoichiometry of ARF and Mdm2 regulates Mycinduced apoptosis and lymphoma development. Schematics of the ARF-Mdm2-p53 tumor suppressor pathway in Em-myc transgenic mice of the indicated genotype. The pathway illustrated for wild-type Em-myc transgenics (furthest left) is altered for each of the genotypes to the right to reflect the changes that occur in the pathway as a consequence of ARF and/or Mdm2 haploinsufficiency. Smaller symbols of ARF and Mdm2 indicate heterozygosity, whereas the different sizes of the p53 symbols represent the differences in activation of p53. In ARF þ /À Em-myc transgenic mice (second from left), there is less ARF to regulate Mdm2, and this leads to decreased p53 activation and apoptosis and accelerated lymphoma development Eischen et al., 1999) . The levels of Mdm2 in Mdm2 þ /À Em-myc transgenics (third from the left) are too low to regulate p53 effectively, resulting in increased apoptosis and inhibition of lymphoma development (Alt et al., 2003) . In ARF þ /À Mdm2 þ /À Em-myc transgenics (furthest right), the decreased levels of ARF allow for a sufficient level of Mdm2 to regulate p53 and re-establish the equilibrium in the pathway; consequently, B-cell apoptosis and lymphoma development are restored to wild-type Em-myc transgenic rates (Figures 4 and 6 ) Stott et al., 1998; Russell et al., 2002; Tolbert et al., 2002; O'Leary et al., 2004) . For example, death caused by lethal doses of gamma irradiation of Mdm2 þ /À and Mdm2 hypomorphic mice, which express lower levels of Mdm2 protein, is not affected by deletion of ARF (O' Leary et al., 2004) . Loss of ARF also fails to rescue the lethality of Mdm2-null embryos (CM Eischen, unpublished data), and the reduced body weights and decreased lymphocyte numbers in Mdm2 hypomorphic mice are unaltered by deletion of ARF (O' Leary et al., 2004) . Consistent with the former reports, we show here that in Mdm2 þ /À Em-myc transgenic mice, loss of only one allele of ARF restored to wild-type B-cell development, susceptibility to apoptosis, lymphoma latency, and the spectrum of genetic alterations selected for during lymphomagenesis. Additionally, deletion of ARF rescued the high levels of spontaneous apoptosis that are a hallmark of Mdm2 þ /À pre-B cells in tissue culture. Thus, our genetic data support and extend earlier in vitro findings Eischen et al., 1999; Schmitt et al., 1999; Sherr and DePinho, 2000) that ARF regulates Mdm2 in B cells when Myc is overexpressed and in pre-B cells in tissue culture. However, our data also show that the increased activation of p53 in Mdm2 þ /À mice from gamma irradiation is reduced to wild-type activity with loss of one allele of ARF. Collectively, these results indicate that ARF is required to regulate Mdm2 in certain scenarios, but not in others, and thus, this pathway must be dependent on other factors and/or signaling pathways.
ARF and Mdm2 cooperate in tumorigenesis
Several studies implicate the cooperation of ARF loss and Mdm2 overexpression on cell cycle and tumorigenesis (Lundgren et al., 1997; Eischen et al., 1999; Foster and Lozano, 2002; Alt et al., 2003; Moore et al., 2003) , and that this can occur in a p53-independent manner. Specifically, defects in mammary gland development are accentuated in ARF-null mice overexpressing Mdm2 in breast epithelial cells (Foster and Lozano, 2002) . These Mdm2-mediated mammary gland defects also occurred in p53-null mice (Lundgren et al., 1997) . Additionally, in lymphomas that arise in ARF-null Em-myc transgenics, or in lymphomas from wild-type Em-myc transgenics bearing deletions of ARF, Mdm2 is overexpressed in at least half of these tumors (Eischen et al., 1999 (Eischen et al., , 2001 . Moreover, Mdm2 is frequently overexpressed in lymphomas that have mutated p53 (Eischen et al., 1999; Alt et al., 2003) . These results would suggest that ARF deletion or p53 mutation and Mdm2 overexpression are two separate selected events during tumor development that independently contribute to lymphomagenesis. Indeed, a deficiency in ARF and overexpression of Mdm2 has been shown by others to be capable of accelerating tumor development (Moore et al., 2003) . This decreased tumor latency in ARF-null/Mdm2-overexpressing mice is purported to be independent of p53, as loss of both p53 and ARF did not alter tumor latency Moore et al., 2003) . Therefore, loss of ARF and overexpression of Mdm2 may be a common denominator of some tumor types, and this may be independent of their effects on p53 function.
Mdm2 as a therapeutic target in tumors lacking ARF
Previous studies have shown that ARF overexpression blocks Mdm2's ability to inhibit p53 (reviewed by Sherr and Weber, 2000) . We show here that the primary role of Myc-induced ARF is to regulate Mdm2. However, our findings also reveal that Mdm2 levels regulate the effects of ARF expression. Specifically, ARF-null pre-Bcell growth rates were reduced to those of wild-type pre-B cells by decreasing Mdm2 levels. Additionally, B cells lacking ARF are normally resistant to the apoptotic effects of Myc (Eischen et al., 1999; Schmitt et al., 1999 ), yet loss of one allele of Mdm2 conferred sensitivity to Myc-induced apoptosis and inhibited Myc-induced lymphomagenesis in Em-myc transgenics that were also haploinsufficient for ARF. These results suggest that modulating Mdm2 levels or function would have significant impact on tumors bearing alterations in ARF expression. In accordance with this idea, Mdm2 antisense oligonucleotides, which can induce apoptosis of a variety of human cancer cell lines, have recently been used to treat several kinds of cancers in xenograft models (Wang et al., 2001) . Other approaches being investigated primarily by the pharmaceutical industry are to identify small molecules that inhibit Mdm2 and p53 interactions (Chene, 2003; Vassilev et al., 2004) or Mdm2's E3 ubiquitin ligase activity (Sun, 2003) . Therefore, such approaches should be particularly beneficial to treat tumors that have inactivated ARF and still express wild-type p53.
Materials and methods
Transgenic and knockout mice
The congenic C57Bl/6 Em-myc transgenic mouse strain (Adams et al., 1985) 
Em-myc, and wildtype Em-myc transgenics. Nontransgenics were also generated from the F1 crosses and used as littermate controls where indicated. All mice were monitored daily for disease, and all research with these mice complied with federal, state, and institutional guidelines. A Kaplan-Meier survival analysis was performed for each genotype. Since the Kaplan-Meier plot ( Figure 6 ) includes mice that were still alive at the time the plot was generated, these cases are right censored because the study was terminated before death occurred. To determine the statistical significance of the survival between the different genotypes of Em-myc transgenic mice, log-rank tests were performed.
Isolation and culture of primary pre-B cells
Bone marrow of 9-to 12-week-old wild-type, Mdm2
Em-myc transgenic, and wild-type Em-myc transgenic mice was placed into tissue culture to select for the outgrowth of pure (>98%) populations of pre-B cells (CD19 þ , B220 þ , CD43 À , IgM À ), as previously described (Eischen et al., 1999) . Phenotype analysis was performed 7-14 days postexplant with fluorescent B-cell-specific antibodies from Southern Biotechnology (Birmingham, AL, USA) and PharMingen (San Diego, CA, USA), and flow cytometry (FACSCalibur; BD Immunocytometry Systems, San Jose, CA, USA) verified that the cells in culture were pre-B cells.
Viability and apoptosis assays
Bone marrow was explanted into IL-7-containing medium on day 0 (see above), and cell viability was determined at specific intervals by Trypan blue dye exclusion. For apoptosis measurements, pre-B cells or disaggregated splenocytes were stained with PI without or with, respectively, ethanol fixation. The FACSCaliber was used to analyse the PI-stained samples, and CellQuest software (BD Immunocytometry Systems, San Jose, CA, USA) was used to quantitate fragmented (sub-G1) DNA.
Phenotype analysis
Whole spleens from wild-type, Mdm2 Em-myc transgenic mice were minced and strained through a 100 mm nylon filter and red blood cells were lysed. Splenocytes were incubated with one to three fluorescently labeled antibodies (CD19-PE, IgM-FITC, B220-CyChrome, and/or fluorescent isotype controls) per sample and evaluated on a FACSCalibur instrument. Data were analysed with CellQuest software.
Gamma irradiation
Wild-type, Mdm2 
Mdm2
þ /À littermates were unirradiated or subjected to whole-body gamma irradiation (10 Gy) from a 137 cesium irradiator. After 4 h, mice were sacrificed and spleens collected and frozen for later analysis. Four separate litters of mice were used for these analyses.
Western blotting
Frozen mouse spleens of various genotypes and pre-B/B-cell lymphomas (3-5 mm 3 chunk) were lysed and protein was extracted as previously described Eischen et al., 1999) . Equal amounts of protein were separated by SDS-PAGE, transferred to nitrocellulose membranes (Protran, Schleicher and Schuell, Dassel, Germany), and blotted with antibodies specific for p19 ARF (GeneTex, San Antonio, TX, USA), p53 (Ab-7, Calbiochem, La Jolla, CA, USA), Mdm2 (C-18, Santa Cruz Inc., Santa Cruz, CA, USA), p21 (F5, Santa Cruz), and b-actin (Sigma, St Louis, MO, USA). HRP-linked secondary antibodies (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and Pierce Supersignal (Rockford, IL, USA) were used to detect bound immunocomplexes.
Southern blotting and sequencing
Genomic DNA from each of the lymphomas that emerged in ARF
Em-myc transgenic mice was digested with AflII or BamHI. Following electrophoretic separation and transfer to Nytran (Scheicher and Schuell, Dassel, Germany) membranes, the digested DNAs were probed with radioactive cDNAs coding ARF (exon 1b) (for AflII-digested DNA) and p53 (exons 2-10) (for BamHI-digested DNA). Genomic DNA from ARF þ /À , ARF À/À , and p53 À/À mice was used for controls. p53 was sequenced from RT-PCR products from RNA isolated from lymphomas arising in ARF
Em-myc transgenic, as previously described (Eischen et al., 1999) .
